These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

130 related items for PubMed ID: 7535121

  • 21. Dopamine-releasing action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 1-methyl-4-phenylpyridine (MPP+) in the neostriatum of the rat as demonstrated in vivo by the push-pull perfusion technique: dependence on sodium but not calcium ions.
    Sirinathsinghji DJ, Heavens RP, McBride CS.
    Brain Res; 1988 Mar 08; 443(1-2):101-16. PubMed ID: 3258784
    [Abstract] [Full Text] [Related]

  • 22. Impairment of the neuronal dopamine transporter activity in MPP(+)-treated rat was not prevented by treatments with nitric oxide synthase or poly(ADP-ribose) polymerase inhibitors.
    Barc S, Page G, Barrier L, Piriou A, Fauconneau B.
    Neurosci Lett; 2001 Nov 13; 314(1-2):82-6. PubMed ID: 11698152
    [Abstract] [Full Text] [Related]

  • 23. Studies on the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: inhibition of NAD-linked substrate oxidation by its metabolite, 1-methyl-4-phenylpyridinium.
    Vyas I, Heikkila RE, Nicklas WJ.
    J Neurochem; 1986 May 13; 46(5):1501-7. PubMed ID: 3485701
    [Abstract] [Full Text] [Related]

  • 24. Evidence for hydroxyl radical scavenging action of nitric oxide donors in the protection against 1-methyl-4-phenylpyridinium-induced neurotoxicity in rats.
    Banerjee R, Saravanan KS, Thomas B, Sindhu KM, Mohanakumar KP.
    Neurochem Res; 2008 Jun 13; 33(6):985-95. PubMed ID: 17763941
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Protective effects of synthetic kynurenines on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice.
    Acuña-Castroviejo D, Tapias V, López LC, Doerrier C, Camacho E, Carrión MD, Mora F, Espinosa A, Escames G.
    Brain Res Bull; 2011 May 30; 85(3-4):133-40. PubMed ID: 21419832
    [Abstract] [Full Text] [Related]

  • 27. Succinobucol, a Non-Statin Hypocholesterolemic Drug, Prevents Premotor Symptoms and Nigrostriatal Neurodegeneration in an Experimental Model of Parkinson's Disease.
    Santos DB, Colle D, Moreira EL, Hort MA, Godoi M, Le Douaron G, Braga AL, Assreuy J, Michel PP, Prediger RD, Raisman-Vozari R, Farina M.
    Mol Neurobiol; 2017 Mar 30; 54(2):1513-1530. PubMed ID: 26852411
    [Abstract] [Full Text] [Related]

  • 28. D-deprenyl protects nigrostriatal neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity.
    Muralikrishnan D, Samantaray S, Mohanakumar KP.
    Synapse; 2003 Oct 30; 50(1):7-13. PubMed ID: 12872288
    [Abstract] [Full Text] [Related]

  • 29. Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 1-methyl-4-phenylpyridinium ion on activities of the enzymes in the electron transport system in mouse brain.
    Mizuno Y, Sone N, Saitoh T.
    J Neurochem; 1987 Jun 30; 48(6):1787-93. PubMed ID: 3106573
    [Abstract] [Full Text] [Related]

  • 30. EGb761 protects against nigrostriatal dopaminergic neurotoxicity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice: role of oxidative stress.
    Rojas P, Serrano-García N, Mares-Sámano JJ, Medina-Campos ON, Pedraza-Chaverri J, Ogren SO.
    Eur J Neurosci; 2008 Jul 30; 28(1):41-50. PubMed ID: 18662333
    [Abstract] [Full Text] [Related]

  • 31. Ferrous-citrate complex and nigral degeneration: evidence for free-radical formation and lipid peroxidation.
    Mohanakumar KP, de Bartolomeis A, Wu RM, Yeh KJ, Sternberger LM, Peng SY, Murphy DL, Chiueh CC.
    Ann N Y Acad Sci; 1994 Nov 17; 738():392-9. PubMed ID: 7832447
    [Abstract] [Full Text] [Related]

  • 32. Neuropharmacological manipulations with MPTP.
    Barnes NJ, Bradbury AJ, Costall B, Domeney AM, Kelly ME, Naylor RJ.
    J Neural Transm Suppl; 1986 Nov 17; 20():47-63. PubMed ID: 3091761
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. In brown Norway rats, MPP+ is accumulated in the nigrostriatal dopaminergic terminals but it is not neurotoxic: a model of natural resistance to MPTP toxicity.
    Zuddas A, Fascetti F, Corsini GU, Piccardi MP.
    Exp Neurol; 1994 May 17; 127(1):54-61. PubMed ID: 8200437
    [Abstract] [Full Text] [Related]

  • 36. [Experimental model of Parkinson disease: mechanisms and anatomo- pathological characteristics of MPTP neurotoxicity].
    Herrero MT, Luquín MR, Obeso JA.
    Arch Neurobiol (Madr); 1992 May 17; 55(4):175-82. PubMed ID: 1417423
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Prevention of the nigrostriatal toxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by inhibitors of 3,4-dihydroxyphenylethylamine transport.
    Mayer RA, Kindt MV, Heikkila RE.
    J Neurochem; 1986 Oct 17; 47(4):1073-9. PubMed ID: 3489072
    [Abstract] [Full Text] [Related]

  • 39. Release of dopamine by perfusion with 1-methyl-4-phenylpyridinium ion (MPP(+)) into the striatum is associated with hydroxyl free radical generation.
    Obata T, Yamanaka Y, Kinemuchi H, Oreland L.
    Brain Res; 2001 Jul 06; 906(1-2):170-5. PubMed ID: 11430875
    [Abstract] [Full Text] [Related]

  • 40. The toxic actions of MPTP and its metabolite MPP+ are not mimicked by analogues of MPTP lacking an N-methyl moiety.
    Bradbury AJ, Costall B, Domeney AM, Testa B, Jenner PG, Marsden CD, Naylor RJ.
    Neurosci Lett; 1985 Oct 24; 61(1-2):121-6. PubMed ID: 2417166
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.